Sippican Capital Advisors’s Eterna Therapeutics ERNA Stock Holding History

Sippican Capital Advisors’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-400	Closed	-$1.99K	–	113
2026 Q1	$1.99K	Hold	400	–	–	﹤0.01%	107
2025 Q4	$12K	Hold	400	–	–	0.01%	112
2025 Q3	$10.9K	Hold	400	–	–	0.01%	114
2025 Q2	$18.4K	Buy	400 +187	+88%	+$13.4K	0.01%	112
2025 Q1	$14.2K	Buy	213 +80	+60%	+$9.87K	0.01%	109
2024 Q4	$14.7K	Sell	133 -50	-27%	-$13.6K	0.01%	112
2024 Q3	$71.9K	Sell	183 -11	-6%	-$7.04K	0.05%	113
2024 Q2	$133K	Hold	194	–	–	0.11%	110
2024 Q1	$175K	Buy	194 +50	+35%	+$34.5K	0.14%	111
2023 Q4	$97K	Buy	144 +69	+92%	+$39.5K	0.08%	114
2023 Q3	$61.3K	Buy	75 +17	+29%	+$15.7K	0.06%	107
2023 Q2	$48.8K	Buy	58 +22	+61%	+$22.2K	0.05%	100
2023 Q1	$45.9K	Buy	+36	New	+$54.2K	0.04%	99
2022 Q4	–	Sell	-5	Closed	-$9K	–	100
2022 Q3	$9K	Buy	+5	New	+$17.2K	0.01%	99

Other funds holding ERNA

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Sippican Capital Advisors's ERNA Position: Q2 2026 in Review

Sippican Capital Advisors sold out of Eterna Therapeutics (ERNA) in Q2 2026, closing a stake of 400 shares — an estimated $1.99K sold.

Sippican Capital Advisors first reported a position in ERNA in Q3 2022 and held it in 14 quarters. The position peaked at $175K in Q1 2024. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

Sippican Capital Advisors reported no remaining Eterna Therapeutics position as of Q2 2026 after selling out during the quarter.
Sippican Capital Advisors sold 400 Eterna Therapeutics shares in Q2 2026, an estimated $1.99K.
Sippican Capital Advisors first reported a position in Eterna Therapeutics in Q3 2022 and held it in 14 quarters.
Sippican Capital Advisors's Eterna Therapeutics position peaked at $175K in Q1 2024.
9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on Sippican Capital Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.